Surgery Partners, Inc.

SGRY

CIK 0001638833 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$885M
↑+2.4% +$21Mvs FY2024 (Q4)
Operating Income
$110M
↓-13.3% -$17Mvs FY2024 (Q4)
Net Income
$29M
Gross Profit
$885M
↑+2.4% +$21Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
29/100
  • Profitability
    6ROIC 6.2% (10% = solid, 20%+ = moat)
  • Liquidity
    68Current Ratio 1.87 (above 1.5 = solid)
  • Leverage
    0D/E 2.18 (under 0.5 = conservative)
  • Efficiency
    16Asset Turnover 0.41x (1.0+ = capital-efficient)
  • Growth
    25Revenue YoY +2.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    60Op Margin 12.5% · trend +0.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project SGRY's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 35.7%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$51.29
Total enterprise IV
$6.52B
Diluted shares
0.13B
Terminal PV
$5.07B (78% of total)
Year-5 FCF
$597M
YearProjected FCFDiscounted PV
+1$245M$222M
+2$306M$253M
+3$382M$287M
+4$478M$326M
+5$597M$371M
Terminal$8.16B$5.07B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$79M
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$17M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$8.12B
everything owned
Stockholders' equity
$1.71B
shareholder claim
Net debt
$3.50B
LT debt minus cash

Recent performance · 50 quarters

Revenue↑+2.4% +$21M
$885M
Net Income
$29M
Free Cash Flow↑+1.7% +$2M
$91M
Operating Margin↓-2.3pts
12.5%

Drill down